Akt2 - AKT serine/threonine kinase 2 Gene

中文名称：AKT 丝氨酸/苏氨酸激酶 2

种属: Rattus norvegicus

基因 ID: 25233 | 基因类型: protein coding

关于 Akt2

Primary_assembly 1: 82,883,547-82,933,817 forward strand.mRatBN7.2:CM026974.1

This gene has 4 transcripts (splice variants), 237 orthologues, 5 paralogues and is associated with 31 phenotypes. Biased expression in Muscle (RPKM 265.6), Heart (RPKM 231.4) and 9 other tissues.

功能概要

该基因编码的蛋白可启动 ATP 绑定活动；蛋白激酶 C 结合活性；和蛋白丝氨酸/苏氨酸激酶活性。参与多个过程，包括氮化合物代谢过程的负调控；积极调节葡萄糖输入；氮化合物代谢过程的正向调控。在细胞对胰岛素刺激的反应和钠离子转运的正调节作用的上游或细胞内起作用。位于多个细胞成分中，包括胰岛素反应室；线粒体；和肌浆网。用于研究高级神经胶质瘤和局部缺血。结直肠癌生物标志物；肝细胞癌；高血压;和肥胖。该基因的人类直系同源物与葡萄糖代谢疾病有关（多个）；伴有偏侧肥大的低胰岛素血症；和生殖器官癌（多发性）。与人类 AKT2（AKT 丝氨酸/苏氨酸激酶 2）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables ATP binding activity; protein kinase C binding activity; and protein serine/threonine kinase activity. Involved in several processes, including negative regulation of nitrogen compound metabolic process; positive regulation of glucose import; and positive regulation of nitrogen compound metabolic process. Acts upstream of or within cellular response to Insulin stimulus and positive regulation of sodium ion transport. Located in several cellular components, including insulin-responsive compartment; mitochondrion; and sarcoplasmic reticulum. Used to study high grade glioma and ischemia. Biomarker of colorectal cancer; hepatocellular carcinoma; hypertension; and obesity. Human ortholog(s) of this gene implicated in glucose metabolism disease (multiple); hypoinsulinemic hypoglycemia with hemihypertrophy; and reproductive organ Cancer (multiple). Orthologous to human Akt2 (Akt serine/threonine kinase 2). [provided by Alliance of Genome Resources, Apr 2022]

Akt2 基因产物(1)

mRNA	Protein	Name
NM_017093.1	NP_058789.1	RAC-beta serine/threonine-protein kinase

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables ATP binding	IDA IDA: 通过直接分析推断	9880520	RGD
enables protein binding	IPI IPI: 通过物理相互作用推断	15684423	RGD
enables protein kinase C binding	IPI IPI: 通过物理相互作用推断	7488143	RGD
enables protein serine/threonine kinase activity	IDA IDA: 通过直接分析推断	9880520	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in cellular response to hormone stimulus	IEP IEP: 通过表达模式推断	15196698	RGD
acts upstream of or within cellular response to insulin stimulus	IMP IMP: 通过突变表型推断	17715136	RGD
involved in cellular response to organic cyclic compound	IDA IDA: 通过直接分析推断	11812651	RGD
involved in negative regulation of RNA splicing	IMP IMP: 通过突变表型推断	19116344	RGD
involved in negative regulation of apoptotic process	IMP IMP: 通过突变表型推断	19084003	RGD
involved in negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	IMP IMP: 通过突变表型推断	18348079	RGD
involved in phosphatidylinositol 3-kinase/protein kinase B signal transduction	IMP IMP: 通过突变表型推断	16469952	RGD
involved in positive regulation of D-glucose import	IMP IMP: 通过突变表型推断	18335029	RGD
involved in positive regulation of cell migration	IMP IMP: 通过突变表型推断	19330838	RGD
involved in positive regulation of gene expression	IMP IMP: 通过突变表型推断	15557754	RGD
involved in positive regulation of nitric oxide biosynthetic process	IMP IMP: 通过突变表型推断	18335029	RGD
involved in positive regulation of peptidyl-serine phosphorylation	IMP IMP: 通过突变表型推断	18348079	RGD
involved in positive regulation of positive chemotaxis	IDA IDA: 通过直接分析推断	19330838	RGD
involved in positive regulation of protein phosphorylation	IMP IMP: 通过突变表型推断	19116344	RGD
involved in positive regulation of signal transduction	IMP IMP: 通过突变表型推断	19084003	RGD
acts upstream of or within positive regulation of sodium ion transport	IMP IMP: 通过突变表型推断	17715136	RGD
involved in positive regulation of transcription by RNA polymerase II	IMP IMP: 通过突变表型推断	16469952	RGD
involved in protein phosphorylation	IDA IDA: 通过直接分析推断	9880520	RGD
involved in response to hypoxia	IEP IEP: 通过表达模式推断	29676955	RGD
involved in response to insulin	IDA IDA: 通过直接分析推断	15684423	RGD
involved in response to insulin	IEP IEP: 通过表达模式推断	18335029	RGD
involved in response to muscle activity	IEP IEP: 通过表达模式推断	11809761	RGD
involved in response to nutrient levels	IEP IEP: 通过表达模式推断	18094069	RGD

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in insulin-responsive compartment	IDA IDA: 通过直接分析推断	9516411	RGD
located in sarcoplasmic reticulum	IDA IDA: 通过直接分析推断	29676955	RGD
located in vesicle	IDA IDA: 通过直接分析推断	9880520	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Akt2 蛋白结构

PH_PKB

STKc_PKB_beta

0
100
200
300
400
496 a.a.

蛋白主名

其他名称

RAC-beta serine/threonine-protein kinase

AKT2 kinase	PKB beta
RAC protein kinase beta RAC-PK beta	RAC-PK-beta
murine thymoma viral (v-akt) oncogene homolog 2	protein kinase Akt-2
protein kinase B beta	thymoma viral proto-oncogene 2
v-akt murine thymoma viral oncogene homolog 2

相关产品

Approval

生物活性分子 (1)

目录号	产品名	作用方式	纯度	是否罕见病
HY-15431	Capivasertib	Inhibitor	99.84%	否

抗体抑制剂 (1)

目录号	产品名	作用方式	纯度	是否罕见病
HY-P99118	Serplulimab	Inducer	99.30%	否

Clinical Phase

生物活性分子 (19)

目录号	产品名	作用方式	纯度	Phase
HY-15186	Ipatasertib	Inhibitor	99.88%	Phase 4
HY-N0004	Oridonin	Inhibitor	99.89%	Phase 4
HY-15186A	Ipatasertib dihydrochloride	Inhibitor	99.27%	Phase 4
HY-15727	Afuresertib	Inhibitor	99.53%	Phase 3
HY-15727A	Afuresertib hydrochloride	Inhibitor	99.95%	Phase 3
HY-10358	MK-2206 dihydrochloride	Inhibitor	99.99%	Phase 2
HY-19719	Miransertib	Inhibitor	99.32%	Phase 2
HY-15965	Uprosertib	Inhibitor	99.93%	Phase 2
HY-108232	MK-2206	Inhibitor	99.72%	Phase 2
HY-19934A	Pifusertib hydrochloride	Inhibitor	99.90%	Phase 2
HY-19719A	Miransertib hydrochloride	Inhibitor	99.74%	Phase 2
HY-19934	Pifusertib	Inhibitor	98.74%	Phase 2
HY-10357	MK-2206 free base	Inhibitor	/	Phase 2
HY-15965A	Uprosertib hydrochloride	Inhibitor	/	Phase 2
HY-10249	GSK-690693	Inhibitor	99.03%	Phase 1
HY-100018	BAY1125976	Inhibitor	99.52%	Phase 1
HY-16071	AT13148	Inhibitor	99.20%	Phase 1
HY-137458	Vevorisertib	Inhibitor	98.03%	Phase 1
HY-15186C	Ipatasertib tosylate	Inhibitor	/	Phase 1

Pre-clinical Phase

生物活性分子 (23)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-10355	AKT inhibitor VIII	Inhibitor	98.97%	否
HY-10425	Rizavasertib	Inhibitor	99.71%	否
HY-133120	INY-03-041	Inhibitor	99.74%	否
HY-151504	Engasertib	Inhibitor	99.65%	否
HY-12059	AT7867	Inhibitor	99.85%	否
HY-13260	CCT128930	Inhibitor	99.69%	否
HY-137458A	Vevorisertib trihydrochloride	Inhibitor	99.13%	否
HY-145282	MS170	Inhibitor	98.68%	否
HY-19982	AKT-IN-6	Inhibitor	99.08%	否
HY-50862	Akt1/Akt2-IN-1	Inhibitor	99.30%	否
HY-12059A	AT7867 dihydrochloride	Inhibitor	99.73%	否
HY-16666	3CAI	Inhibitor	98.32%	否
HY-132302	Hu7691	Inhibitor	99.91%	否
HY-133120A	INY-03-041 trihydrochloride	Inhibitor	98.44%	否
HY-13260A	CCT128930 hydrochloride	Inhibitor	98.97%	否
HY-126257	AKT-IN-3	Inhibitor	98.12%	否
HY-129119	Akt1/Akt2-IN-2	Inhibitor	98.57%	否
HY-151613	MS15	Inhibitor	/	否
HY-145281	MS98	Inhibitor	/	否
HY-132302A	Hu7691 free base	Inhibitor	/	否
HY-138767	AKT-IN-5	Inhibitor	/	否
HY-143611	AKT-IN-8	Inhibitor	/	否
HY-16032	Akt1-IN-2	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Akt2	NCBI	NCBI:208
Mus musculus	Akt2	NCBI	NCBI:11652

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4